Swiss financial group Cedrus invests in big health in China

Cedrus Group, a Swiss global investment firm with a 15-year presence in China, recently completed its latest investment round in Hainan Leyun Biotechnology Co., Ltd., a Chinese scientific research and reproductive anti-aging company. The investment, amounting to several million dollars, further expands Cedrus’ footprint in China.

With its huge population and vast middle class, the Chinese market continues to attract foreign capital. Cedrus Group is one of the many investors drawn to this dynamic market. At the opening ceremony of its Asia-Pacific Headquarters in May, the group announced plans to invest 1 billion yuan ($139.4 million) in developing healthcare and related innovative technologies on the Chinese mainland, including drug research and development, in vitro fertilization, and nanotechnology devices.

For the past 15 years, Cedrus has been committed to helping global companies navigate the highly competitive and complex life sciences industry, earning the trust of numerous partners. Given its preference for medical research in China, Cedrus has expanded its presence in first-tier cities such as Beijing, Shanghai, Hong Kong, and Shenzhen. Additionally, Cedrus plans to establish several private equity funds on the Chinese mainland this year, with an overall size exceeding 1.5 billion yuan.